Skip to main content

Year: 2024

RBB Bancorp Reports Third Quarter 2024 Earnings and Declares Quarterly Cash Dividend of $0.16 Per Common Share

LOS ANGELES, Oct. 21, 2024 (GLOBE NEWSWIRE) — RBB Bancorp (NASDAQ:RBB) and its subsidiaries, Royal Business Bank (the “Bank”) and RBB Asset Management Company (“RAM”), collectively referred to herein as “the Company,” announced financial results for the quarter ended September 30, 2024. Third Quarter 2024 HighlightsNet income totaled $7.0 million, or $ 0.39 diluted earnings per share Return on average assets of 0.72%, compared to 0.76% for the quarter ended June 30, 2024 Net interest margin of 2.68% compared to 2.67% for the quarter ended June 30, 2024 Repurchased 508,275 shares of common stock for $11.0 million during the quarter ended September 30, 2024, and completed the authorized program Book value and tangible book value per share(1) increased to $28.81 and $24.64 at September 30, 2024, up from $28.12 and $24.06 at June...

Continue reading

Nokia Corporation: Repurchase of own shares on 21.10.2024

Nokia CorporationStock Exchange Release21 October 2024 at 22:30 EET Nokia Corporation: Repurchase of own shares on 21.10.2024 Espoo, Finland – On 21 October 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows:Trading venue (MIC Code) Number of shares Weighted average price / share, EUR*XHEL 1,317,830 4.34CEUX 269,017 4.32BATE – –AQEU – –TQEX – –Total 1,586,847 4.33* Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program started on 20 March 2024. On 19 July 2024, Nokia decided to accelerate the share buybacks by...

Continue reading

Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion

Treatment of a subgroup of patients with post-acute sequelae of SARS-CoV-2. Forecast adds to Tevogen Bio’s Oncology therapeutic area projections of $1 billion in the launch year and $10–$14 billion over the first five years.WARREN, N.J., Oct. 21, 2024 (GLOBE NEWSWIRE) — Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today announced its top-line revenue forecast for its specialty care pipeline, projecting nearly $1 billion in revenue in its launch year and a cumulative 5-year estimate of between $18 billion and $22 billion. This forecast reflects the company’s unique, faster, and cost-efficient drug development model which has the potential...

Continue reading

LINCOLN TECH ANNOUNCES PARTNERSHIP WITH HYUNDAI MOTOR AMERICA & GENESIS MOTOR AMERICA; TRAINING OFFERED AT NO ADDITIONAL COST TO STUDENTS

New career training option will help meet growing nationwide demand for Hyundai and Genesis automotive technicians. PARSIPPANY, NJ – October 21, 2024, Oct. 21, 2024 (GLOBE NEWSWIRE) — Lincoln Educational Services Corporation (NASDAQ: LINC), a national leader in specialized technical training for more than 75 years, has partnered with Hyundai Motor America (HMA) & Genesis Motor America (GMA) to launch two new employer-specific training programs. These programs will supplement Lincoln Tech’s Automotive Service Technology programs across the country and help students build skills on Hyundai/Genesis equipment and systems, while helping the employer build its technician workforce. Interested students will have the chance to select between the Hyundai Performance Institute Technician Student Program or the Genesis Technician Student...

Continue reading

BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

CARSON CITY, Nev., Oct. 21, 2024 (GLOBE NEWSWIRE) — BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the pricing of a registered direct offering of 4,443,000 shares of its common stock priced at-the-market under Nasdaq rules at a price of $1.50 per share, resulting in total gross proceeds of $6,664,500, before deducting the placement agent’s fees and offering expenses. The Company also agreed to issue to the investors unregistered warrants to purchase up to 4,443,000 shares of common stock in a concurrent private placement. The warrants will have an exercise price of $1.37 per share of common stock, will be exercisable beginning...

Continue reading

Embassy Bank voted the 2024 Morning Call Readers’ Choice “Best Bank” and Grows Market Share in Lehigh & Northampton Counties Combined with Year over Year Deposit Growth

BETHLEHEM, Pa., Oct. 21, 2024 (GLOBE NEWSWIRE) — Embassy Bancorp, Inc. (OTCQX: EMYB) – Embassy Bank for the Lehigh Valley is thrilled and deeply honored to announce that the bank has been named this year’s 2024 Morning Call Readers’ Choice for “BEST BANK” in the Lehigh Valley. This recognition reinforces Embassy’s commitment, first made nearly 23 years ago, to exceed customer expectations while setting the standard in community banking. The Bank offers innovative banking solutions, attentive personal service and expert professional guidance, enabling customers to achieve their full financial potential.  Since its inception in November 2001, the Bethlehem-based Bank has consistently achieved annual deposit growth in the two-county region of Pennsylvania. The Federal Deposit Insurance Corporation’s Summary of Deposits (SOD)...

Continue reading

Puma Exploration Accelerates Acquisition of Claims at Williams Brook

RIMOUSKI, Quebec, Oct. 21, 2024 (GLOBE NEWSWIRE) — Puma Exploration Inc. (TSXV: PUMA, OTCQB: PUMXF) (the “Company” or “Puma”) reports that it has satisfied, ahead of schedule, the requirements for its purchase of 100% interest in 341 claims (“the Claims”) announced on March 1, 2022. The Claims cover the Panthera Gold Zone and the newly discovered Lion Gold Zone. To complete its acquisition of 100% interest in the Claims, Puma had an obligation to issue the Vendor 250,000 common shares of the Company and a C$50,000 cash payment on or before February 2025 (the agreement’s third anniversary). This agreement, amongst others, negotiated by Puma to extend its property, was the last to be fully executed. The 100%-owned Williams Brook Gold Project includes the Williams Brook, Portage and Jonpol properties (Figure 1). Figure...

Continue reading

VEON Welcomes Letter from its Shareholder Shah Capital, Reiterates Commitment to Shareholder Value Creation

Amsterdam and Dubai, 21 October 2024: VEON Ltd. (Nasdaq: VEON; Euronext Amsterdam: VEON), a global digital operator (“VEON” or the “Company”), acknowledges the receipt of a letter from Shah Capital (the “Shah Letter”), a valued long-term shareholder holding approximately 7% of VEON’s shares, to the VEON Board of Directors (“VEON Board”). The letter, which outlines Shah Capital’s views on VEON’s current valuation and suggests a seven-step strategic roadmap to enhance shareholder value, has been reviewed by VEON’s Board of Directors and the Management team. VEON thanks Shah Capital for their continued support and feedback; and welcomes the opportunity to address the issues highlighted in the Shah Letter, initially with a response from VEON Board to Shah Capital shared earlier today, and also in the longer term through continued communication.  ...

Continue reading

Hi-View Announces Private Placement

VANCOUVER, British Columbia, Oct. 21, 2024 (GLOBE NEWSWIRE) — Hi-View Resources Inc. (‘Hi-View’ or the ‘Company’) (CSE: HVW; OTCQB: HVWRF; FSE: B63) is pleased to announce it is launching a non-brokered private placement of up to 5,000,000 units (the “Units”), at a price of $0.02 per Unit for gross proceeds of up to $100,000 (the “Offering”). The Units will consist of one common share of the Company (“Share”) and one share purchase warrant (“Warrant”). Each Warrant will be exercisable by the warrant holder to acquire one (1) additional Share at a price of CAD$0.05 for a period of 24 months from the closing of the Offering. Hi-View will use the net proceeds from the Offering for general working capital. The issuance of securities in connection with this Offering will be subject to Canadian Securities...

Continue reading

Tevogen Bio Provides Clarity on CSO Share Sales to Satisfy Tax Obligations, Expects Additional Forecast and Progress Updates in the Coming Days

WARREN, N.J., Oct. 21, 2024 (GLOBE NEWSWIRE) — Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, reported last week that Chief Scientific Officer (CSO) Dr. Neal Flomenberg sold shares. Tevogen’s Chief Financial Officer, Kirti Desai, clarified that the sale was made solely to satisfy the payment of tax obligations relating to the vesting of restricted stock units and was not made at the discretion of the CSO. Other officers, the Chief Executive Officer, the Chief Financial Officer, and the Chief Commercial Officer, who hold more than 75% of total outstanding shares in aggregate, have already paid taxes when shares were granted and have no further...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.